David Malcom Rodman insider trades: Mineralys Therapeutics (MLYS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where David reports to the SEC
Open-market buys and sales
36 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | MLYS | ↓ Sell | 2,170 | $27.09 | $59K | Direct | Aug 12, 2026 (2d) |
| Jul 17, 2026 | MLYS | ↓ Sell | 416 | $26.53 | $11K | Direct | Jul 20, 2026 (3d) |
| Jul 15, 2026 | MLYS | ↓ Sell | 20,407 | $27.28 | $557K | Direct | Jul 15, 2026 (0d) |
| Jul 9, 2026 | MLYS | ↓ Sell | 2,171 | $30.30 | $66K | Direct | Jul 10, 2026 (1d) |
| Jun 17, 2026 | MLYS | ↓ Sell | 14,474 | $24.19 | $350K | Direct | Jun 17, 2026 (0d) |
| Jun 12, 2026 | MLYS | ↓ Sell | 8,519 | $24.20 | $206K | Direct | Jun 12, 2026 (0d) |
| May 18, 2026 | MLYS | ↓ Sell | 417 | $27.55 | $11K | Direct | May 19, 2026 (1d) |
| May 13, 2026 | MLYS | ↓ Sell | 22,575 | $28.91 | $653K | Direct | May 13, 2026 (0d) |
| Apr 17, 2026 | MLYS | ↓ Sell | 416 | $31.33 | $13K | Direct | Apr 21, 2026 (4d) |
| Apr 15, 2026 | MLYS | ↓ Sell | 20,406 | $26.89 | $549K | Direct | Apr 15, 2026 (0d) |
| Apr 9, 2026 | MLYS | ↓ Sell | 2,170 | $27.38 | $59K | Direct | Apr 13, 2026 (4d) |
| Mar 17, 2026 | MLYS | ↓ Sell | 417 | $25.65 | $11K | Direct | Mar 17, 2026 (0d) |
| Mar 13, 2026 | MLYS | ↓ Sell | 20,406 | $26.61 | $543K | Direct | Mar 16, 2026 (3d) |
| Mar 9, 2026 | MLYS | ↓ Sell | 2,171 | $26.84 | $58K | Direct | Mar 10, 2026 (1d) |
| Feb 17, 2026 | MLYS | ↓ Sell | 417 | $27.59 | $12K | Direct | Feb 17, 2026 (0d) |
| Feb 13, 2026 | MLYS | ↓ Sell | 20,404 | $27.93 | $570K | Direct | Feb 13, 2026 (0d) |
| Feb 9, 2026 | MLYS | ↓ Sell | 2,171 | $30.21 | $66K | Direct | Feb 11, 2026 (2d) |
| Jan 20, 2026 | MLYS | ↓ Sell | 416 | $32.10 | $13K | Direct | Jan 20, 2026 (0d) |
| Jan 12, 2026 | MLYS | ↓ Sell | 8,518 | $32.56 | $277K | Direct | Jan 13, 2026 (1d) |
| Jan 5, 2026 | MLYS | ↓ Sell | 262,752 | $35.25 | $9.3M | Direct | Jan 6, 2026 (1d) |
| Oct 15, 2025 | MLYS | ↓ Sell | 10,369 | $43.01 | $446K | Direct | Oct 15, 2025 (0d) |
| Sep 15, 2025 | MLYS | ↓ Sell | 11,367 | $36.00 | $409K | Direct | Sep 16, 2025 (1d) |
| Aug 13, 2025 | MLYS | ↓ Sell | 11,365 | $12.93 | $147K | Direct | Aug 14, 2025 (1d) |
| Jul 14, 2025 | MLYS | ↓ Sell | 11,366 | $14.59 | $166K | Direct | Jul 15, 2025 (1d) |
| Jun 13, 2025 | MLYS | ↓ Sell | 11,366 | $14.60 | $166K | Direct | Jun 16, 2025 (3d) |
| May 14, 2025 | MLYS | ↓ Sell | 11,366 | $15.29 | $174K | Direct | May 15, 2025 (1d) |
| Apr 14, 2025 | MLYS | ↓ Sell | 11,366 | $14.53 | $165K | Direct | Apr 15, 2025 (1d) |
| Apr 1, 2025 | MLYS | ↓ Sell | 55,771 | $15.76 | $879K | Direct | Apr 3, 2025 (2d) |
| Nov 11, 2024 | MLYS | ↓ Sell | 5,026 | $15.00 | $75K | Direct | Nov 12, 2024 (1d) |
| Nov 6, 2024 | MLYS | ↓ Sell | 25,482 | $15.03 | $383K | Direct | Nov 8, 2024 (2d) |
| Jul 16, 2024 | MLYS | ↓ Sell | 525 | $15.00 | $8K | Direct | Jul 18, 2024 (2d) |
| May 9, 2024 | MLYS | ↓ Sell | 100 | $15.00 | $2K | Direct | May 10, 2024 (1d) |
| Aug 11, 2023 | MLYS | ↓ Sell | 231,716 | $12.92 | $3.0M | Direct | Aug 11, 2023 (0d) |
| Jan 4, 2017 | NVLS | ↓ Sell | 6,687 | $2.27 | $15K | Direct | Jan 5, 2017 (1d) |
| Oct 4, 2016 | NVLS | ↓ Sell | 5,820 | $7.96 | $46K | Direct | Oct 5, 2016 (1d) |
| Jul 5, 2016 | NVLS | ↓ Sell | 5,950 | $4.66 | $28K | Direct | Jul 6, 2016 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other MLYS insiders
Open-market trades in the last 12 months
About David Malcom Rodman's insider trades
David Malcom Rodman is Chief Medical Officer at Mineralys Therapeutics (MLYS). Since Jul 5, 2016, David has reported no open-market purchases and 36 sales worth $19.4M on SEC Form 4. In the last 12 months: 20 sales ($13.3M).
Their filings also include option exercises (51 filings), grants and awards (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MLYS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.